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Introduction
　In the human genome, G-protein coupled receptors (GP-
CRs) are encoded by approximately 826 genes, forming the 
largest family of membrane molecules. They have been 
found to be associated with various diseases and exert vari-
ous types of bioactivity by binding to endogenous ligands 
including hormones, growth factors, and neurotransmitters 
(1). With regard to their involvement in autoimmune dis-
eases, autoantibodies against a rhodopsin subfamily in GP-
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CRs have been found to be associated with the molecular 
condition of several diseases. For example, there have been 
reports on the involvement of autoantibodies against thy-
roid-stimulating hormone receptors in Gravesʼ disease (2), 
autoantibodies against adrenalin beta-1 receptors and mus-
carinic acetylcholine receptor (AChR) type 2 in cardiovas-
cular disease (3-5), antibodies against muscarinic AChR 
type 1 in chronic fatigue syndrome (6,7), as well as autoan-
tibodies against muscarinic AChR type 3 in Sjögrenʼs syn-
drome (SS) and in acquired idiopathic generalized anhidro-
sis (8,9). 
　GPCRs consist of an extracellular-facing amino-terminal 
(N-terminal) region and an intracellular-facing carboxyl-
terminal (C-terminal), with seven transmembrane regions. 
Therefore, to analyze the epitope of these antibodies, the ex-
tracellular facing N-terminal and three extracellular loops 
(ECL1–3) are usually examined. However, given the spatial 
structure of the extracellular region and post-translational 
modification, antigens should ideally be used under condi-
tions in which they adopt structures close to those occurring 
naturally. In this respect, the cell-based assay (CBA) is a 
suitable method to detect antibodies against multipass trans-
membrane molecules, such as GPCRs (10-12). CBA has the 
highest sensitivity for antibody detection among conven-
tional diagnostic methods because of the following reasons: 
1) it is used with living cells that express full-length antigen-
encoding genes, thereby ensuring that the spatial structure 
and post-translational modification is very similar to the 
natural membrane molecule, i.e., the antigen, 2) it enables 
selective detection of antibodies that interact in the extracel-
lular region, and 3) it utilizes a measuring device equipped 
with a fluorescence detector. Therefore, among existing an-
tibody measurement technologies, CBA is particularly out-
standing in the analysis of antibodies that target membrane 
molecules. Two principal types of fluorescence detectors are 
used in CBA. These are fluorescence microscope and flow 
cytometer. The former is used to determine the presence or 
absence of antibodies upon imaging, making it unsuitable 
for quantitative analysis, while the latter enables quantitative 
analysis. However, both devices are extremely expensive 
laboratory equipment and are not readily available to general 
laboratories. Furthermore, a certain level of expertise is re-
quired to operate such equipment.
　An antibody detection technique that has gained recent 
attention is the luciferase immunoprecipitation system 
(LIPS) (13, 14). In LIPS, antibodies are detected with a lu-
ciferase reporter in which an antigenic polypeptide is fused 
to a luciferase at its amino- or carboxyl-terminus, and be-
cause it is used for luciferase reporter genes expressed in 
cells, it ensures correct post-translational modification of an-
tigenic membrane molecules. Furthermore, as the lumines-
cence-measuring device (luminometer) is less expensive 
than fluorescence microscopes and flow cytometers and can 
be operated easily, it is a promising technological substitu-
tion for CBA. It has been reported that LIPS is capable of 
detecting various types of autoantibodies; however, very few 
reports have mentioned antibodies that target membrane 
molecules such as GPCR. Therefore, in the present study, we 
thoroughly examined the application of LIPS in the detec-
tion of GPCR antibodies with the view of optimization.
Materials and Methods
Ethics
　The study was approved by the Ethics Committee of Na-
gasaki University Graduate School of Biomedical Sciences 
(Nagasaki, Japan). Written informed consent was obtained 
from each subject, in person, prior to participation in the 
study. This process was documented by means of an ap-
proved consent form.
Patients and serum samples
　Serum samples were available for 39 (2 males and 37 fe-
males) patients with definite SS (mean age, 58.4 ± 11.8 
years old) recruited through Nagasaki Kawatana Medical 
Center and Nagasaki University Graduate School of Bio-
medical Sciences. These samples represented both primary 
SS (n = 31) and secondary SS (n = 8). We also tested 39 se-
rum samples from healthy volunteers (mean age, 46 years 
old; male: female ratio, 2:37). They were also recruited from 
Nagasaki Kawatana Medical Center and Nagasaki Univer-
sity Graduate School of Biomedical Sciences. 
The diagnosis of SS was established by the criteria proposed 
by the Diagnostic Committee of Health and Welfare of Japan 
(15) or by the American-European Consensus Group (16).
Cells, DNA, and antibodies
　FreeStyle 293 cells (293F) were obtained from Invitro-
gen. Cells were cultured and maintained in Dulbeccoʼs mod-
ified Eagle medium (DMEM, Gibco) supplemented with 
10% fetal bovine serum (FBS, Gibco). Human muscarinic 
AChR type 3 (M3R) cDNA was obtained from Promega 
(FHC10778). Gaussia luciferase (GL) cDNA was purchased 
from pBasic-Gluc (New England Biolabs). GL8990 (F89W 
and I90L) is one of the GL mutants generated by site-direct-
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ed mutagenesis and emits 10 times stronger and/or prolonged 
bioluminescence than intact GL (17). pcDNA3.1-Myc/His 
(A) was obtained from Invitrogen. Antibodies recognizing 
the N- and C-terminal portions of human M3R, H-20 (goat 
IgG), and H-210 (rabbit IgG), were purchased from Santa 
Cruz Biotechnology, Santa Cruz, CA. Alexa Fluor®488 
sheep anti-goat IgG antibody and Alexa Fluor®488 goat anti-
rabbit IgG antibody were acquired from Molecular Probes.
Construction of M3R-GL8990 expression plasmids
　The human M3R-GL8990 plasmid was constructed by clon-
ing the full-length of human M3R cDNA upstream of the 
GL8990 using BamHI/AgeI restriction sites in pcDNA3.1-
Myc/His (A). Construction of luciferase reporter expression 
plasmids of ganglionic acetylcholine receptor (gAChR) has 
been described elsewhere (18). All plasmids were purified 
using the Labo Pass™ Mini Kit (Hokkaido System Science). 
Conventional LIPS (cLIPS)
 
　293F cells were transfected with M3R-GL8990 expression 
plasmids using FuGENE6 (Promega). Two days later, trans-
fected cells were solubilized with Tris-based saline contain-
ing 1% TritonTM X-100. A total of 50 μl of the soluble frac-
tion was mixed with anti-M3R antibodies (H-20 or H-210, 
Santa Cruz Biotechnology), 15 μl of protein G-sepharose 
(PGS, GE Healthcare), and 600 μl phosphate-buffered sa-
line with 3% bovine serum albumin (BSA) and 0.05% 
Tween® 20, and incubated overnight at 4 ℃ with a rotator. 
Following precipitation and washing of PGS, biolumines-
cence activity of the luciferase reporters in the PGS was 
measured using the BioLuxTM Gaussia Luciferase Assay Kit 
(New England Biolaboratories) and a Lumat LB 9507 lumi-
nometer (Berthold Technologies). The luminometer output 
was measured in relative luminescence units (RLU). 293F 
cells expressing luciferase reporters for two different subunit 
of gAChR (AChRα3-GL8990 and AChRβ4-GL8990) were 
used as a negative control in cLIPS.
Cell-based assay (CBA) using fluorescence microscope
　To detect serum antibodies binding to M3R on living cells, 
a CBA using fluorescence microscope was designed. In 
brief, 293F cells were cultured on 6-well multidish collagen 
(Nalge Nunc International) in 1 ml DMEM supplemented 
with 10% FBS. Cells were transfected with M3R expression 
plasmid (0.8 µg per well) using FuGENE6 (Promega; 3 µL 
per well) and were used for immunostaining after 18 h. Cells 
expressing M3R were incubated with H-20 or H-210 anti-
M3R antibody for 1 h in a CO2 incubator; they were then 
washed once with the Opti-MEM medium (Gibco). Further, 
cells were incubated with 1 µL of Alexa Fluor®488 donkey 
anti-goat IgG or goat anti-rabbit IgG antibody for 30 min in 
a CO2 incubator; they were then extensively washed with 
Opti-MEM medium. Immunofluorescence images were ana-




　293F cells were inoculated in 6-well multidish collagen 
and cultured in 1 ml of DMEM supplemented with 10% 
FBS. 293F cells were transfected with 0.5 μg of luciferase 
expression plasmids by 2 μl of FuGENE6 (Promega) per 
well. Eighteen hours later, antibody or antiserum was added 
to culture wells and incubated for 1 h at 37 ℃ in a CO2 incu-
bator. Cells were washed twice with 1 ml PBS and lysed 
with 200 µl cell-lysis buffer (20 mM Tris-HCl, pH 7.5; 100 
mM NaCl, 1% Triton X-100). Cell lysates were centrifuged 
at 21,130 × g at 4 ℃ for 15 min, after which, soluble frac-
tions were collected. A total of 170 μl of the soluble fraction 
was mixed with 500 μl of PBS with 3% BSA, 0.05% Tween 
20, and 15 μl (volume of resin) PGS, and the mixture was 
incubated for several hours or overnight at 4 ℃ with a rota-
tor. The PGS was precipitated at 9,391 × g for a few sec and 
extensively washed with PBS supplemented with 0.05% 
Tween20 (PBST) up to two times. Luminescence activity 
was measured as described above. 293F cells expressing lu-
ciferase reporters for two different subunit of gAChR 
(AChRα3-GL8990 and AChRβ4-GL8990) were used as a 
negative control in mLIPS. To normalize the transfection ef-
ficiency of M3R-GL8990 in each well, a net of luciferase ac-
tivity in 20 µl of the soluble fraction was measured. Anti-
body levels were finally expressed as arbitrary units (A.U.) 
calculated as follows: 
A.U. = [mLIPS measurement value of sample (RLU)]/[mea-
surement value of 20 μl of soluble fraction value (RLU)].
mLIPS for human sera
　mLIPS was performed as described above. A total of 15 
μl human serum was used in this experiment. Based on the 
data from 39 human control sera for anti-M3R antibodies, 
cut-off values were calculated as the mean + four standard 
deviations (SD) from the mean. In this study, antibody titers 
were expressed as an antibody index (A.I.) calculated as fol-
lows: 
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A.I. = [measurement value of the sample serum (RLU)]/[the 
cut-off value (RLU)]. 
　The normal value established in this study from healthy 
individuals was <1.0 A.I. The autoimmune autonomic gan-
glionopathy patient serum has been tested positive for anti-
gAChR antibody in the previous study (18).
Statistical analysis
　Commercially available statistics software was used for 
data analysis (SigmaPlot®). A.I. data that were normally dis-
tributed were analyzed by one-way analysis of variance 
(ANOVA). For data that were not normally distributed, the 
one-way ANOVA of ranks was employed. The level of sta-




　To know whether M3R-GL8990 works in a conventional 
LIPS (cLIPS), we first used two ready-made antibodies for 
human M3R. H-20 and H-210 antibodies are generated 
against the N-terminal portion and ICL3 of human M3R, re-
spectively (Figure 1). As shown in Figure 2a, both H-20 and 
H-210 antibodies were adequately detected. On the other 
hand, when using the soluble fraction prepared from cells 
with gAChR reporters that have low amino sequence homol-
ogy with M3R, we were unable to detect either antibody 
(Figure 2a). These data demonstrated that M3R-GL8990 
was applicable to cLIPS.
mLIPS
　We next tried a modified application of the cLIPS, termed 
modified LIPS (mLIPS). In brief, serum antibodies bind to 
M3R-GL8990 in living cells in a new technique (Supple-
mentary Figure 1). H-20 antibodies were detected at 0.1-1.0 
μg/ml in a dose-dependent manner, but H-210 antibodies 
were not detected even at 0.3 μg/ml. In mLIPS using cells 
that expressed gAChR-GL8990 as a control, H-20 antibodies 
were not detected at all. We then performed CBA with a 
fluorescence microscope to compare antibody detection sen-
sitivity. The fluorescent signals of H-20 antibody were obvi-
ously visible 0.06-0.6 μg/ml (Figure 3a). In contrast, H-210 
antibody was not detected even at 0.6 μg/ml in mLIPS (Fig-
ure 3b).
Screening of autoantibodies for M3R in human sera
　It is known that M3R antibodies can be detected in the 
blood of patients with SS and acquired idiopathic general-
ized anhidrosis. In the present study, we performed mLIPS 
using the serum of 39 SS patients enrolled through the Naga-
saki University First Department of Internal Medicine. As a 
result, we identified one patient with antibody-positive se-
rum exceeding the cut-off value based on analysis of serum 
from healthy individuals (Figure 4). We also found that the 
increase in reporter activity was proportional to the increase 
in antibody-positive serum (Figure 5a). To test the specificity 
of antigen of SS patient serum, gAChR-GL expressing cells 
were used. As shown in Figure 5b, the reporter activity of 
gAChR-GL was increased in dose-dependent-manner of 
anti-gAChR antibody-positive autoimmune autonomic gan-
glionopathy (AAG) patient serum, but not anti-M3R anti-
body-positive SS serum. 
Figure 1. Schematic representation of human muscarinic acetyl-
choline receptor type-3. Muscarinic acetylcholine receptor type-
3 (M3R) has seven membrane spanning domains (purple bars) 
and localizes at the cell plasma membrane (blue bar). The amino-
terminal portion and the three extracellular loops (ECL1–3) are in 
the extracellular space. Carboxyl-terminal portions and the three 
intracellular loops (ICL1–3) are in the intracellular area. M3R 
interacts with G-protein at ICL3. Two ready-made antibodies, 
H-20 (red Y-shaped line) and H-210 (green Y-shaped line), have 
epitopes in the amino-terminal portion and ICL3 of human M3R, 
respectively. 
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Figure 2. Detection of anti-M3R antibodies with conventional LIPS and modified LIPS. 
(a) Reporter-specific detection of anti-M3R antibodies by the conventional luciferase immunoprecipitation systems (cLIPS). De-
tection of two-types of anti-M3R antibodies by cLIPS with M3R-GL8990 and ganglionic acetylcholine receptor (gAChR)-GL8990 
. Circles and squares indicate M3R-GL8990 and gAChR-GL8990, respectively. Closed and open symbols indicate H-20 and H-210 
antibodies, respectively. The y-axis indicates luciferase reporter activity (relative luminescence units, RLU). The x-axis indicates 
concentrations of anti-M3R antibodies (µg/ml) in log scale. Error bars indicate standard deviations (SD) from the mean (n = 3). 
We evaluated that two lines with circle symbols shows dose-response manner (one way-ANOVA comparisons were performed us-
ing the Student-Newman-Keuls method in each reaction between reporter gene and antibody: P < 0.001), but not two lines with 
square symbols. (b). Specific detection of the antibody that binds the amino-terminal portion of M3R in the modified luciferase 
immunoprecipitation systems (mLIPS). Detection of anti-M3R antibodies by mLIPS with M3R-GL8990 and gAChR-GL8990. Closed 
and open symbols indicate H-20 and H-210 antibodies, respectively. Circles and squares indicate M3R-GL8990 and gAChR-GL8990, 
respectively. The y-axis indicates arbitrary units (A.U.; see “Materials and Methods”). The x-axis indicates concentrations of anti-
M3R antibodies (µg/ml) in log scale. Error bars indicate standard deviations (SD) from the mean (n = 3). We evaluated that a line 
with closed circles shows dose-response manner (one way-ANOVA comparisons were performed using the Student-Newman-Keuls 
method in each reaction between reporter gene and antibody: P < 0.001), but not two lines with open circles and closed squares.
Figure 2.	
a	 b	
Figure 4. Anti-muscarinic acetylcholine receptor type-3 (M3R) 
antibody in Sjögrenʼs syndrome (SS) patient sera samples, as de-
termined by the modified luciferase immunoprecipitation systems 
(mLIPS).
One anti-M3R antibody-positive serum sample was identified 
by mLIPS among 39 SS patient samples. Open circles and open 
squares indicate data from healthy controls (HC) and from SS 
patients SS), respectively. Solid and broken lines indicate the 
means of data from HC and SS, respectively. The y-axis indicates 
antibody index (A.I.; described in “Materials and Methods”). 
Arrow indicates the cut-off value of 1.0.
Figure 3. Detection of anti-muscarinic acetylcholine receptor 
type-3 (M3R) antibodies in the cell-based assay (CBA) using fluo-
rescence microscopy.
Living cells expressing M3R-GL8990 were stained with H-20 (a) 
or H-210 antibody (b) and secondary antibody-conjugated with 
Alexa488. The concentrations of H-20 antibody were as indicated. 
The concentration of H-210 antibody was 600 ng/ml. Scale bars 
indicate 100 µm. 
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Figure 5. Examination of the antigen specificity of SS patient serum in mLIPS.
Luciferase activity of M3R-GL8990 increased in a dose-dependent manner of anti-M3R antibody-positive serum. The y-axis indi-
cates antibody index (A.I.; described in “Materials and Methods”). The x-axis indicates the volume of anti-M3R antibody-pos-
itive serum (µl) in log scale. b) No increase of the luciferase activity of gAChR-GL8990 was observed in mLIPS with anti-M3R 
antibody-positive serum (Open circles). In contrast, the luciferase activity of gAChR-GL8990 increased in a dose-dependent man-
ner of an AAG patient serum (Closed circles). y-axis indicates arbitrary units (A.U.; see “Materials and Methods”). The x-axis 
indicates the volume of human serum (µl) in log scale.
Supplementary Figure 1. Contrast between conventional luciferase immunoprecipitation systems (cLIPS) and modified LIPS 
(mLIPS).
In cLIPS (the left panel), M3R-GL8990 is expressed at the plasma membrane (Step I) and then is solubilized with a cell lysis buf-
fer containing a detergent (Step II). Magenta and cyan colors indicate the extracellular and intracellular portions, respectively. 
Yellow color indicates luciferase. Solubilized M3R-GL8990 is mixed with antibodies (Step III). Red and green Y-shaped lines 
indicate H-20 and H-210 antibodies, respectively. In step IV, anti-M3R antibodies binding M3R-GL8990 are concentrated using 
protein G-sepharose (Orange circle). In contrast, in mLIPS (the right panel), luciferase reporters are bound to antibodies before 
cell solubilization (Step II). As a result, antibodies recognizing extracellular portions, but not intracellular regions, are selectively 
concentrated using protein G-sepharose (Step IV).
Figure 5. 	
b	a	
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　In this study, we demonstrated that mLIPS was one of the 
most suitable tools for selective detection of antibodies that 
recognizes extracellular portions of antigen. As reporters are 
solubilized after expression on the cell membrane, there is 
the risk of destroying the spatial structure of antigen proteins 
when using cLIPS. There is also the possibility that antigens 
bound to the intracellular region will also be detected (Sup-
plementary Figure 1, left panel). Therefore, based on CBA 
application, we devised a modified protocol for LIPS, 
mLIPS, in which cells producing reporters on the membrane 
and antibodies were left to react in advance; then, after the 
antibody–antigen complex had formed, the cells were solu-
bilized (Supplementary Figure 1, right panel). Several exist-
ing autoantibodies against GPCR target muscarinic AChRs 
(5-9). Therefore, in the present study, we chose to target 
muscarinic AChR type 3 (M3R). M3Rs have seven trans-
membrane regions and are located on the cell membrane 
with four extracellular-facing regions, including the N-ter-
minal portion and ECL 1–3 (Figure 1). On the other hand, 
the C-terminal portion and intracellular loop (ICL) 1–3 are 
intracellular-facing (Figure 1). In cLIPS, H-210 antibody 
with an epitope in ICL3 was detected (Figure 2a), whereas 
the antibody was not detected in mLIPS (Figure 2b). The 
large number of existing autoantibodies target intracellular 
antigens, such as antinuclear antibodies. However, the un-
derlying pathogenicity remains unclear. Antibodies with ex-
tracellular epitopes include those that cause V-type allergies 
(Gravesʼ disease-related autoantibodies) and those that cause 
complement-mediated tissue destruction (myasthenia grav-
is-related autoantibodies), which have a direct interaction 
with the onset of diseases (2, 19). Consequently, a develop-
ment of diagnostic method to detect autoantibodies binding 
the extracellular regions of membrane proteins with a high 
sensitivity has been desired intensely. Our mLIPS enables 
selective detection of such pathogenic autoantibodies (Fig-
ure 2b). Furthermore, mLIPS and CBA possibly have equal 
sensitivity in terms of antibody detection, at least for H-20 
antibodies (Figures 2b and 3). mLIPS is easier to operate and 
is a less expensive measurement device with quantitative ca-
pacity and in these respects has the potential to be an alterna-
tive to CBA in the near future.
　The detection of antibodies that recognize the spatial 
structure of membrane molecules using cLIPS remains con-
troversial. Compared with the detection sensitivity in the 
conventional radioimmunoassay (RIA) for myasthenia grav-
is-related autoantibodies against muscular nicotinic AChRs, 
that of cLIPS was very low (20). Muscular nicotinic AChR 
forms a pentamer composed of four different subunits (alpha 
1, beta 1, delta, and epsilon/gamma). In general, a pentamer 
form of AChR is used in the RIA for detecting of anti-mus-
cular nicotinic AChR antibody. In brief, AChRs bound with 
125I-bungarotoxin (Btx) are first mixed with human serum. If 
there is anti-AChR antibody in human serum, it could form 
an immunocomplex with AChRs. The radioactivity of im-
munocomplex indicates a level of anti-AChR antibody in 
human serum (21). In the LIPS performed by Ching et al, the 
alpha1 subunit fused to luciferase was used as a luciferase 
reporter in the absence of other subunits (20). They claimed 
that this might be attributed to the fact that antibodies against 
spatial structures formed between other subunits in the pen-
tamer cannot be detected in cLIPS using a luciferase reporter 
of alpha 1 subunit. In contrast, Nakane et al. used cLIPS us-
ing a luciferase reporter of ganglionic nicotinic acetylcho-
line receptor (gAChR) for detecting of autoantibodies in 
autoimmune autonomic ganglionopathy (AAG) (18). It is 
known that gAChR is mainly composed of two subunits (al-
pha 3 and beta 4) (22). A single subunit (alpha 3 or beta 4 
subunit) is used in their study. However, they observed no 
major differences of the prevalence of antibody in AAG rela-
tive to the conventional RIA (18). Therefore, the applicabil-
ity of cLIPS for antibodies to multispan membrane proteins 
can be described on a case-by-case basis because only a 
small number of cases have been examined (18, 20). How-
ever, when analyzing antibodies to multispan membrane 
proteins expected to have a complex spatial structure, mLIPS 
should be chosen as the first-line tool to minimize the risk of 
destroying the spatial structure of the target antigen as much 
as possible.
　For detection sensitivity of antibody in mLIPS, an effect of 
the internalization of M3R following to antibody binding re-
mains elusive. It has been reported that a half of M3R on cell 
surface was internalized after attacking of anti-M3R antibody 
to cells (23). In this study, we performed a binding reaction 
between antibody and antigen at 37℃ for one hour, whereas a 
possibility that an internalization of antigen at cell surface de-
creases a sensitivity of antibody in mLIPS is not excluded. 
However, we think that a part of antibodies internalized could 
be detected by mLIPS if before internalized antibodies are de-
graded in cellular organelle such as lysosome. 
　Finally, one SS patient serum containing anti-M3R anti-
body was identified with mLIPS, demonstrating that this 
new technique is applicable to human biospecimens. In the 
near future, mLIPS may prove to be a powerful diagnostic 
tool to detect pathogenic autoantibodies for GPCRs and con-
tribute to screening of therapeutic antibodies directed at GP-
CRs (24). 
Discussion
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